Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to brain tumor research. The ABTA has since expanded its mission and now provides comprehensive resources to support the complex needs of brain tumor patients and caregivers, across all ages and tumor types, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnoses, treatments and care.
BTG Specialty Pharmaceuticals provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. We are dedicated to the development, manufacture, and commercialization of quality medicines that make a real difference to patients and their families. BTG Specialty Pharmaceuticals is now part of Boston Scientific. To learn more, please visit: www.btgplc.com/pharmaceuticals
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
A leader in precision radiation medicine, Elekta’s innovative neuroscience solutions include Leksell Gamma Knife® Icon™, enabling precision cranial radiosurgery; Leksell Gamma Knife® Lightning, a treatment optimizer designed to boost workflows and improve plan quality; and Vantage™ Stereotactic System, a solution for accurate localization and treatment of intracranial targets in neurosurgery.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. By investing over $60M early in 2020, HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs, ITI is well-positioned to accelerate its immuno-oncology platform, in particular glioblastoma multiforme, and rapidly advance other key candidates in our pipeline, including the most recent initiative into infectious diseases with development of its vaccine candidate for COVID-19. All program areas are driven by ITI’s UNITE™ platform.
Lead by pediatric neurooncologist Dr. Maryam Fouladi and pediatric neurosurgeon Dr. Jeffery Leonard, the Neuro-Oncology Program is engaged through leadership and clinical trials in every major national neuro-oncology consortium including CONNECT, NEXT, PBTC, PNOC, and COG. The Neuro-Oncology team provides international collaboration and support to peers in Central and South America through the Global Outreach Program, the first of its kind in pediatric-oncology. Through the Head Start 4 protocol, Nationwide Children's leads over 50 sites from around the world to improve the quality of survival and cure rates for young children with primitive neuro-ectodermal tumors. And we continue to treat patient families from around the globe including Canada, Poland, Saudi Arabia, South Africa, China, and throughout the United States. Named to the Top 10 Honor Roll on U.S. News & World Report’s 2020-21 list of “Best Children’s Hospitals,” Nationwide Children’s Hospital is one of America’s largest not-for-profit freestanding pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease.
NeuroBlate is a surgical tool used to ablate a wide variety of lesions, including brain tumors and radiation necrosis. NeuroBlate delivers safe, maximal cytoreduction for patients and is supported by a growing body of clinical evidence. Recent studies have shown that patients who have undergone the NeuroBlate procedure have: • Short hospital stays • Minimal complications • Low readmission rates
Optune is a portable, noninvasive, antimitotic cancer treatment for newly diagnosed and recurrent Glioblastoma. It provides continuous action against disease progression by delivering Tumor Treating Fields (TTFields) at 200kHZ. TTFields are electric fields delivered in 2 directions to disrupt cancer cell division. TTFields specifically target and disrupt division of GBM cells, inhibiting tumor growth and possibly causing affected cancer cells to die while sparing normal, healthy cells. Optune® Indications for Use and Important Safety Information Indications For Use Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy. For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted. Important Safety Information Contraindications Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective. Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure. Warnings and Precautions Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer). Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established. The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression. The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache. The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer. Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective. If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment. Please see Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions at Optune.com/Safety.
The Sontag Foundation is one of the largest private funders of brain cancer research in the United States. Established in 2002 by Rick and Susan Sontag, the Foundation has committed $30 million dollars to brain cancer research to date. Through its annual Distinguished Scientist Award www.sontagfoundation.org/all-grants/brain-cancer/, the Foundation provides career and research support for the best and brightest early career scientists who, with their sights set on gaining new understanding about brain cancer, ultimately strive to make a difference for patients suffering from this intractable disease. The Brain Tumor Network (BTN), a nonprofit organization launched in 2014 by Rick and Susan Sontag, is a unique navigation resource for patients in the USA with primary brain tumors. By guiding patients and empowering care, BTN's specialized staff provides patients and medical professionals with navigation services to access expanded options- connecting patients to clinical trials, centers of excellence, second opinions and a network of support. BTN services are available without cost to patients, families, and health care providers. The Brain Tumor Network is committed to making a difference—one patient at a time. To learn more, visit BTN at www.braintumornetwork.org. http://sontagfoundation.org/